Evofem — Third Quarter 2026 Earnings Summary

Evofem Biosciences reported net sales of $4.6 million for the third quarter of 2026, a decrease from $5.0 million in the prior year period, primarily due to lower ex-factory sales of PHEXX. The company generated $0.7 million in operating income and $0.9 million in net income attributable to common stockholders for the quarter, contrasting with a net loss in the same period of 2025. Strategic milestones achieved since July 2026 include contracting a second manufacturer for PHEXX production, shipping the 500,000th box of PHEXX, and adding a fifth site to an NIH-funded Phase 4 clinical trial for SOLOSEC. As of September 30, 2026, restricted cash and cash equivalents stood at $0.3 million, reflecting the company's ongoing liquidity position.